PharmaCorp Rx Inc. has completed the purchase of a full interest in a PharmaChoice Canada-bannered pharmacy in Ontario for approximately $8.1 million, paid out of the company's existing cash resources. The deal takes the Saskatoon-based acquirer's operating network to 15 pharmacies.
According to the July 31, 2026 release, the store was bought from an arm's length vendor group and no finder's fees were payable. The company did not disclose the pharmacy's revenue, prescription volume or earnings, so the multiple paid is not determinable from the announcement.
It is the tenth pharmacy PharmaCorp has added through completed acquisitions since August 2025. The company describes itself as a pharmacy acquisition and ownership platform that buys stores from retiring owners and brings pharmacists in as equity partners.
The Ontario deal is the first of two definitive share purchase agreements to close. Both came out of a group of four non-binding letters of intent that PharmaCorp disclosed on April 30, 2026, signed between February 23 and March 23, 2026. A letter of intent is a preliminary document that does not commit either side to complete a transaction.
The second definitive agreement covers a PharmaChoice-bannered pharmacy in Western Canada. PharmaCorp says it has received preliminary approval from the relevant provincial college of pharmacy and expects to close on or about August 17, 2026, subject to customary conditions. If it completes, the network would rise to 16 stores. No purchase price was given for that transaction, nor was a funding source identified.
The remaining two of the original four letters of intent are still being negotiated toward definitive agreements. PharmaCorp has also signed a further non-binding letter of intent dated July 23, 2026 for a pharmacy in Western Canada. Together with a previously disclosed letter dated June 23, 2026, the company says it has four active letters of intent in process. All remain conditional on due diligence and the negotiation of binding contracts.
The release does not state PharmaCorp's remaining cash balance after the $8.1 million payment, nor its debt position, share count or the aggregate cost of the pipeline it is working through. Those figures matter for a company funding acquisitions from its balance sheet: an $8.1 million cash outlay is the kind of number that determines how many further deals can be closed without new equity or borrowing. Investors would need the company's most recent financial statements, filed on SEDAR+, to assess capacity.
PharmaCorp trades on the TSX Venture Exchange under the symbol PCRX.
Source: Newsfile
This article is journalism, not investment advice. It is not an offer or solicitation to buy or sell any security. Micro-cap and penny stocks carry a high risk of loss, including illiquidity and dilution. Do your own research.